A new study published in the Annals of Surgical Oncology has just revealed that peritoneal mesothelioma patients who produce too many blood platelets are probably not good candidates for Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
CRS/HIPEC is a treatment process whereby surgeons remove as much of the mesothelioma tumors from the thin membrane surrounding the abdomen. Then heated medication is used on any of the cancer cells not removed than the surgeon. The CRS/HIPEC treatment combination is the preferred treatment protocol for those patients suffering from peritoneal mesothelioma. The treatment protocol is typically linked to longer survival rates however based on the results from the study the treatment could have a negative impact should the patient’s body produce too many platelets.
The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.
Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers.
